Document is current
Any future updates will be listed below
-
Authors
Garmezy, Benjamin
Vaishampayan, Ulka
-
Funding
Funding for this research was provided by:
Pfizer
- License Information
-
More Information
Article History
Received: 30 December 2023
Accepted: 27 August 2024
First Online: 2 October 2024
Declarations
:
: Discusses are fictional case studies and do not represent actual patient cases. Benjamin Garmezy received institutional research funding from Abbvie, Accutar Biotechnology, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, CRISPR Therapeutics, Eikon Therapeutics, Exelixis, Roche/Genentech, Flare Therapeutics, Harbour BioMed, IDEAYA Biosciences, Janssen, Janux Therapeutics, Jubilant Therapeutics, Kineta, Kinnate BioPharma, Loxo, Mink Therapeutics, Nuvation Bio, Profound Bio, Takeda Theapeutics, Teon Therapeutics, Tmunity Therapeutics, Xencor, and Zenshine and consulting fees/honoraria from for Abbvie, Adaptimmune, Adicent Therapeutics, AIQ Global, Amgen, Arcus Biosciences, Arvinas, AstraZeneca, AVEO Oncology, Bayer, Bicycle Tx, Eisai, EMD Serono, Exelixis, Janssen, Merck, Novartis, Pfizer, Rondo Therapeutics, Sanofi-Aventis, Seagen, and Xencor. Ulka Vaishampayan has received institutional research funding from Merck Inc and consulting fees/honoraria from Bayer, Merck, BMS, Novartis, Exelixis, Pfizer, Janssen, and Gilead Inc.
: This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.
